Dr. Elias J. Jabbour CML Chronic Myeloid Leukemia
Assistant Professor, Department of Leukemia,
Division of Cancer Medicine,
The University of Texas MD Anderson Cancer Center, Houston, TX
Division of Cancer Medicine,
The University of Texas MD Anderson Cancer Center, Houston, TX
VIDEOS
CML Update at ASH 2011 - Interview with Elias Jabbour, M.D.
January 27, 2012, OncUViewTV
Dr. Jabbour on Front-Line Treatments for CML
March 15, 2011, OncLiveTV
Dr. Jabbour on Second-Generation TKIs in CML
March 15, 2011, OncLiveTV
ARTICLES
Expert Insights: CML Updates From Summer 2011
August 17, 2011, Medscape education
Discontinuation of imatinib may be possible in chronic myelogenous leukemia
March 4, 2011, Online Library
Predictive factors for outcome and response in patients treated with second-generation tyrosine kinase inhibitors for chronic myeloid leukemia in chronic phase after imatinib failure
February 10, 2011, Journal Blood
Tyrosine Kinase Inhibitors in CML: Applying New Data to Practice -- An Expert Interview
With Dr. Elias J. Jabbour From ASH 2009
2009, Medscape Education
CML Update at ASH 2011 - Interview with Elias Jabbour, M.D.
January 27, 2012, OncUViewTV
Dr. Jabbour on Front-Line Treatments for CML
March 15, 2011, OncLiveTV
Dr. Jabbour on Second-Generation TKIs in CML
March 15, 2011, OncLiveTV
ARTICLES
Expert Insights: CML Updates From Summer 2011
August 17, 2011, Medscape education
Discontinuation of imatinib may be possible in chronic myelogenous leukemia
March 4, 2011, Online Library
Predictive factors for outcome and response in patients treated with second-generation tyrosine kinase inhibitors for chronic myeloid leukemia in chronic phase after imatinib failure
February 10, 2011, Journal Blood
Tyrosine Kinase Inhibitors in CML: Applying New Data to Practice -- An Expert Interview
With Dr. Elias J. Jabbour From ASH 2009
2009, Medscape Education
